ARTICLE | Clinical News

Enbrel etanercept: Phase II data; marketed to treat rheumatoid arthritis (RA)

August 27, 2001 7:00 AM UTC

IMNX said that Enbrel met its primary endpoint of a significant improvement in PASI 75 after 12 weeks compared to placebo in a Phase II study of 112 patients with moderate to severe plaque psoriasis. ...